MARKER THERAPEUTICS, INC.: 10-Q/A filed 2016-04-14
What MARKER THERAPEUTICS, INC. reported in its quarterly report amendment filed 2016-04-14 (fiscal Q3 2015): 18 published measures, 51 facts as tagged in accession 0001193125-16-541488.
This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.
This filing
- Form
- 10-Q/A (quarterly report amendment)
- Filed
- 2016-04-14
- Fiscal period
- fiscal Q3 2015
- Accession
- 0001193125-16-541488 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All MARKER THERAPEUTICS, INC. filings.
Reported measures
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | -27,390,633 | USD | |
| At 2014-12-31 | -1,023,636 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 28,503,325 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -32,413,693 | USD | 273 |
| 2014-07-01 to 2014-09-30 | -1,567,836 | USD | 92 |
| 2014-01-01 to 2014-09-30 | -30,146,586 | USD | 273 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-09-30 | -3,492,432 | USD | 273 |
| 2014-01-01 to 2014-09-30 | -1,517,944 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-09-30 | 9,437,504 | USD | 273 |
| 2014-01-01 to 2014-09-30 | 2,083,000 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | -131,855,730 | USD | |
| At 2014-12-31 | -86,309,731 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 48,585,003 | shares | 92 |
| 2015-01-01 to 2015-09-30 | 36,651,565 | shares | 273 |
| 2014-07-01 to 2014-09-30 | 17,310,708 | shares | 92 |
| 2014-01-01 to 2014-09-30 | 13,292,886 | shares | 273 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 80,944,993 | shares | 92 |
| 2015-01-01 to 2015-09-30 | 36,651,565 | shares | 273 |
| 2014-07-01 to 2014-09-30 | 17,310,708 | shares | 92 |
| 2014-01-01 to 2014-09-30 | 13,292,886 | shares | 273 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 0.59 | USD/shares | 92 |
| 2015-01-01 to 2015-09-30 | -0.88 | USD/shares | 273 |
| 2014-07-01 to 2014-09-30 | -0.09 | USD/shares | 92 |
| 2014-01-01 to 2014-09-30 | -2.27 | USD/shares | 273 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 0.35 | USD/shares | 92 |
| 2015-01-01 to 2015-09-30 | -0.88 | USD/shares | 273 |
| 2014-07-01 to 2014-09-30 | -0.09 | USD/shares | 92 |
| 2014-01-01 to 2014-09-30 | -2.27 | USD/shares | 273 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-09-30 | 261,805 | USD | 273 |
| 2014-01-01 to 2014-09-30 | 1,265,625 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 6,225,302 | USD | |
| At 2014-12-31 | 224,448 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 33,615,935 | USD | |
| At 2014-12-31 | 1,248,084 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 1,737,978 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 3,904,186 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 1,383,709 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 2,976,681 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 769,219 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 1,579,754 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 32,500 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 77,500 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 62,890,763 | shares | |
| At 2014-12-31 | 20,318,815 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 104,402,206 | USD | |
| At 2014-12-31 | 85,265,776 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-09-30 | -32,413,693 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 968,759 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 2,324,432 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 1,351,209 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 2,899,181 | USD | 273 |
Inspect the source
- Entity
- MARKER THERAPEUTICS, INC. / CIK 0001094038
- Captured
- 2026-09-20T05:22:11.393Z
- SEC response SHA-256
11a45295baae8ad4450041d3d51c2454c6531734b6bbb806e124ea5eb0db02da
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001094038.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))